Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic beta-Catenin, PIK3CA and MET
This shift toward transparency-first communication mirrors larger market movements where wellness brands are increasingly expected to serve as sources of digestible, verifiable product informationwithout crossing into promotional rhetoric
Eli Lilly submitted the orforglipron NDA to the FDA in Q1 2026 following ATTAIN Phase 3 trial data showing 14.7% body weight reduction at 45mg positioning the worlds first oral small molecule GLP-1 receptor agonist for obesity for anticipated FDA approval in late 2026 or 2027
Used to investigate tissue repair, extracellular-matrix signalling, and regenerative biology in cell-based assays and biochemical models under non-clinical conditions
Stemming from these insights, researchers initiated the creation and enhancement of dual-receptor stimulants targeting both GLP-1/glucagon, aiming to counteract DM2 and obesity
So I was thinking, why on Earth shouldnt I suggest that you could actually do both of those things at the same time with one drug? It was 1995 and Knudsen had recently been tasked with figuring out what to do with the companys GLP-1 program, which had been stagnating amid scientific dead-ends and organizational shake-ups
